The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy

INTRODUCTION: EGFR tyrosine kinase inhibitors are one of the key drugs for treatment of NSCLC with EGFR mutations. In recent times, immune check-point inhibitors (ICIs) have also been widely used for patients with NSCLC. Although a subset of patients obtain benefit from ICIs, adverse events (AEs) th...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinno, Yuki, Goto, Yasushi, Ohuchi, Mayu, Hamada, Akinobu, Nokihara, Hiroshi, Fujiwara, Yasuhiro, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474461/
https://www.ncbi.nlm.nih.gov/pubmed/34589912
http://dx.doi.org/10.1016/j.jtocrr.2020.100008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474461/
https://www.ncbi.nlm.nih.gov/pubmed/34589912
http://dx.doi.org/10.1016/j.jtocrr.2020.100008

Ejemplares similares